Thursday, 1 June 2017

EU approves Biogen's Spinraza for lead genetic cause of infant death

(Reuters) - Biogen Inc on Thursday said its drug, Spinraza, had secured European Union approval to treat spinal muscular atrophy (SMA), a leading genetic cause of death in infants.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)